RaySearch Laboratories AB (publ)
OTC:RSLBF
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| SE |
|
RaySearch Laboratories AB (publ)
STO:RAY B
|
6.6B SEK |
Loading...
|
|
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD |
Loading...
|
|
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
29.4B USD |
Loading...
|
|
| AU |
|
Pro Medicus Ltd
ASX:PME
|
13.8B AUD |
Loading...
|
|
| JP |
|
M3 Inc
TSE:2413
|
1.1T JPY |
Loading...
|
|
| SE |
|
Sectra AB
STO:SECT B
|
44.8B SEK |
Loading...
|
|
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.6B USD |
Loading...
|
|
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD |
Loading...
|
|
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
21B CNY |
Loading...
|
|
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR |
Loading...
|
|
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
229.8B INR |
Loading...
|
Market Distribution
| Min | -855 316.7% |
| 30th Percentile | 30.8% |
| Median | 44.8% |
| 70th Percentile | 66% |
| Max | 113 764.6% |
Other Profitability Ratios
RaySearch Laboratories AB (publ)
Glance View
RaySearch Laboratories AB is a medical technology company, which engages in the development of software solutions for improved radiation therapy of cancer. The company is headquartered in Stockholm, Stockholm. The company markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for RaySearch Laboratories AB (publ) is 92.4%, which is above its 3-year median of 90.5%.
Over the last 3 years, RaySearch Laboratories AB (publ)’s Gross Margin has increased from 88.7% to 92.4%. During this period, it reached a low of 88% on Mar 31, 2023 and a high of 93% on Sep 30, 2025.
